2026 ICD-10-CM Diagnosis Code C30.0Malignant neoplasm of nasal cavity
ICD-10-CM Codes›C00–D49›C30-C39›C30
- Billable — Valid for Submission
- Risk Adjusts — HCC 21
- Chronic Condition
C30.0 is a billable ICD-10-CM diagnosis code for malignant neoplasm of nasal cavity. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 11 through 13, 146 through 148. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Head and neck cancers - all other types.
For Medicare Advantage risk adjustment, C30.0 maps to CMS-HCC Category 21 (Lymphoma and Other Cancers) under the V28 model, adding a risk factor of about 0.671 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C30.0 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Carcinoma of nasal cavity
- Carcinoma of nasal meatus
- Carcinoma of nasal septum
- Left primary malignant olfactory neuroblastoma
- Malignant melanoma of nasal cavity
- Malignant neoplasm of cartilage of nose
- Malignant neoplasm of inferior nasal turbinate
- Malignant neoplasm of lateral nasal wall
- Malignant neoplasm of middle nasal turbinate
- Malignant neoplasm of nasal cavities, middle ear and accessory sinuses
- Malignant neoplasm of nasal cavity
- Malignant neoplasm of nasal cavity and nasopharynx
- Malignant neoplasm of nasal conchae
- Malignant neoplasm of nasal septum
- Malignant neoplasm of nasal skeleton
- Malignant neoplasm of nasal vestibule
- Neoplasm of cartilage of nose
- Neoplasm of inferior nasal turbinate
- Neoplasm of lateral nasal wall
- Neoplasm of middle nasal turbinate
- Neoplasm of nasal cavity and nasopharynx
- Neoplasm of nasal vestibule
- Olfactory neuroblastoma
- Primary adenocarcinoma of nasal cavity
- Primary malignant neoplasm of cartilage of nose
- Primary malignant neoplasm of nasal cavity
- Primary malignant neoplasm of nasal concha
- Primary malignant neoplasm of septum of nose
- Primary malignant neoplasm of vestibule of nose
- Primary malignant neuroepitheliomatous neoplasm of nasal cavity
- Primary olfactory neuroblastoma
- Primary squamous cell carcinoma of accessory sinus
- Primary squamous cell carcinoma of naris
- Primary squamous cell carcinoma of nasal cavity
- Primary squamous cell carcinoma of nasal cavity and paranasal sinus
- Right primary malignant olfactory neuroblastoma
- Squamous cell carcinoma of nose
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Malignant neoplasm of cartilage of nose
- Malignant neoplasm of nasal concha
- Malignant neoplasm of internal nose
- Malignant neoplasm of septum of nose
- Malignant neoplasm of vestibule of nose
Type 1 Excludes
- malignant neoplasm of nasal bone C41.0
- malignant neoplasm of nose NOS C76.0
- malignant neoplasm of olfactory bulb C72.2
- malignant neoplasm of posterior margin of nasal septum and choana C11.3
- malignant melanoma of skin of nose C43.31
- malignant neoplasm of turbinates C41.0
- other and unspecified malignant neoplasm of skin of nose C44.301 C44.311 C44.321 C44.391
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Carcinoma (malignant) See Also: Neoplasm, by site, malignant;
unspecified site C30.0
Esthesioneuroblastoma C30.0
Esthesioneurocytoma C30.0
Esthesioneuroepithelioma C30.0
olfactory C30.0
Neuroepithelioma See Also: Neoplasm, malignant, by site;
olfactory C30.0
specified site See: Neoplasm, malignant, by site;
unspecified site C30.0
Tumor See Also: Neoplasm, unspecified behavior, by site;
neurogenic olfactory C30.0
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
| Site | Malig. Primary | Malig. Secondary | Ca in situ | Benign | Uncertain | Unspec. |
|---|---|---|---|---|---|---|
| cartilage (articular) (joint) NEC [See Also: Neoplasm, bone] › nose, nasal | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| cavity › nasal | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| concha [See Also: Neoplasm, skin, ear] › nose | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| mucosa › nasal | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nares, naris (anterior) (posterior) | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nose, nasal › cartilage | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nose, nasal › cavity | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nose, nasal › fossa | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nose, nasal › internal | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nose, nasal › mucosa | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nose, nasal › septum | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nose, nasal › turbinate (mucosa) | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nose, nasal › vestibule | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| nostril | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| septum | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| septum › nasal | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| turbinate (bone) › nasal | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
| vestibule › nose | C30.0 | C78.39 | D02.3 | D14.0 | D38.5 | D49.1 |
Patient EducationClinical
Nasal Cancer
Your paranasal sinuses are small hollow spaces around the nose. They are lined with cells that make mucus, which keeps your nose from drying out. The nasal cavity is the passageway just behind your nose. Air passes through it on the way to your throat as you breathe.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C30.0 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C30.0Overview
What is the ICD-10 code for malignant neoplasm of nasal cavity?
The ICD-10-CM code for malignant neoplasm of nasal cavity is C30.0 (sometimes written as C300). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is C30.0 (Malignant neoplasm of nasal cavity and middle ear) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of nasal cavity on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C30.0 group to?
When malignant neoplasm of nasal cavity is the principal diagnosis on an inpatient stay, it groups to MS-DRG 11, 12, 13, 146, 147, 148, with relative weights from 0.7971 to 5.4541 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of C30.0?
Under the General Equivalence Mappings, malignant neoplasm of nasal cavity converts to ICD-9-CM 160.0 (mal neo nasal cavities). The mapping is a direct match.
What HCC is C30.0?
C30.0 (malignant neoplasm of nasal cavity) maps to CMS-HCC Category 21 (Lymphoma and Other Cancers), commonly written as HCC 21, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 11 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does C30.0 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C30.0 adds a risk adjustment factor of about 0.671 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.493 to 0.739 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, and HCC 20) supersedes it when both are reported. See the full factor table on the HCC 21 category page.
